REFERENCES
1. Zhang Y, Rumgay H, Li M, Yu H, Pan H, Ni J. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Glob Health. 2023;13:04109.
2. Wéber A, Vignat J, Shah R, et al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024;42:237.
3. Leslie SW, Soon-Sutton TL, Aeddula NR. Bladder cancer. StatPearls. Treasure Island (FL); 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536923/. [Last accessed on 12 Aug 2025].
4. Grabe-Heyne K, Henne C, Mariappan P, Geiges G, Pöhlmann J, Pollock RF. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124.
5. Yang Y, Wang C, Li Z, Lu Q, Li Y. Precise diagnosis and treatment of non-muscle invasive bladder cancer - a clinical perspective. Front Oncol. 2023;13:1042552.
6. Kodera A, Mohammed M, Lim P, Abdalla O, Elhadi M. The management of Bacillus Calmette-Guérin (BCG) failure in high-risk non-muscle invasive bladder cancer: a review article. Cureus. 2023;15:e40962.
7. Ferro M, Marchioni M, Lucarelli G, et al. Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. Minerva Urol Nephrol. 2021;73:796-802.
8. Germuth FG Jr, Choi IJ, Taylor JJ, Rodriguez E. Antibasement membrane disease. I. The glomerular lesions of Goodpasture’s disease and experimental disease in sheep. Johns Hopkins Med J. 1972;131:367-84.
9. Zhang H, Li A, Wang W, Xu S, Li C, Teng L. Efficacy and safety of radical cystectomy with ileal conduit for muscle-invasive bladder cancer in the elderly: a multicenter retrospective study. Front Oncol. 2024;14:1402360.
10. Teply BA, Kim JJ. Systemic therapy for bladder cancer - a medical oncologist’s perspective. J Solid Tumors. 2014;4:25-35.
11. Hensley PJ, Bree KK, Campbell MT, et al. Progression of disease after Bacillus Calmette-Guérin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2021;206:1258-67.
13. Wilson F, Joseph N, Choudhury A. Biomarkers in muscle invasive bladder cancer. Adv Clin Chem. 2022;107:265-97.
14. Rahman MM, McFadden G. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers. 2021;13:5452.
15. Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9:122-39.
16. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642-62.
17. Xue C, Lv J, Yang B, et al. Gene therapy in polycystic kidney disease: a promising future. J Transl Int Med. 2024;12:543-52.
18. Hu H, Xia Q, Hu J, Wang S. Oncolytic viruses for the treatment of bladder cancer: advances, challenges, and prospects. J Clin Med. 2022;11:6997.
19. Filon M, Schmidt B. New treatment options for non-muscle-invasive bladder cancer. Am Soc Clin Oncol Educ Book. 2025;45:e471942.
20. Liu X, Zhang J, Feng K, et al. Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: a meta-analysis. Front Pharmacol. 2022;13:1023533.
21. Liu C, Xie J, Lin B, et al. Pan-cancer single-cell and spatial-resolved profiling reveals the immunosuppressive role of APOE+ macrophages in immune checkpoint inhibitor therapy. Adv Sci. 2024;11:e2401061.
22. Yuan S, She D, Jiang S, Deng N, Peng J, Ma L. Endoplasmic reticulum stress and therapeutic strategies in metabolic, neurodegenerative diseases and cancer. Mol Med. 2024;30:40.
23. Cao T, Peng B, Zhou X, et al. Integrated signaling system under endoplasmic reticulum stress in eukaryotic microorganisms. Appl Microbiol Biotechnol. 2021;105:4805-18.
24. Zheng Q, Gu X, He JC, Xie J. Progress in therapeutic targets on podocyte for Alport syndrome. J Transl Int Med. 2024;12:129-33.
25. Kim P. Understanding the unfolded protein response (UPR) pathway: insights into neuropsychiatric disorders and therapeutic potentials. Biomol Ther. 2024;32:183-91.
26. Panayi GS, Corrigall VM. Immunoglobulin heavy-chain-binding protein (BiP): a stress protein that has the potential to be a novel therapy for rheumatoid arthritis. Biochem Soc Trans. 2014;42:1752-5.
27. Haeri M, Knox BE. Endoplasmic reticulum stress and unfolded protein response pathways: potential for treating age-related retinal degeneration. J Ophthalmic Vis Res. 2012;7:45-59.
28. Lebeaupin C, Yong J, Kaufman RJ. The impact of the ER unfolded protein response on cancer initiation and progression: therapeutic implications. In: Mendillo ML, Pincus D, Scherz-Shouval R, editors. HSF1 and molecular chaperones in biology and cancer. Cham: Springer International Publishing; 2020. pp. 113-31.
29. da Fonseca FG, Serufo ÂV, Leão TL, Lourenço KL. Viral infections and their ability to modulate endoplasmic reticulum stress response pathways. Viruses. 2024;16:1555.
30. Cai J, Lin Y, Zhang H, et al. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proc Natl Acad Sci U S A. 2017;114:6812-7.
31. Chen XY, Liu Y, Zhu WB, et al. Arming oncolytic M1 virus with gasdermin E enhances antitumor efficacy in breast cancer. iScience. 2024;27:111148.
32. Lin Y, Zhang H, Liang J, et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc Natl Acad Sci U S A. 2014;111:E4504-12.
33. Hu C, Liu Y, Lin Y, et al. Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer. Cell Death Dis. 2018;9:274.
34. Wang L, Chard Dunmall LS, Cheng Z, Wang Y. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. J Immunother Cancer. 2022;10:e004167.
35. Qiu L, Zheng X, Jaishankar D, et al. Beyond UPR: cell-specific roles of ER stress sensor IRE1α in kidney ischemic injury and transplant rejection. Kidney Int. 2023;104:463-9.
36. Zhang K, Wang S, Malhotra J, et al. The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis. EMBO J. 2011;30:1357-75.
37. Fu F, Doroudgar S. IRE1/XBP1 and endoplasmic reticulum signaling - from basic to translational research for cardiovascular disease. Curr Opin Physiol. 2022;28:100552.
38. Shao R, Liu C, Xue R, et al. Tumor-derived exosomal ENO2 modulates polarization of tumor-associated macrophages through reprogramming glycolysis to promote progression of diffuse large B-cell lymphoma. Int J Biol Sci. 2024;20:848-63.
39. Liu Y, Yu Y, Hu C, et al. ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC. Cancer Drug Resist. 2025;8:25.
40. Zhang YZ, Ma Y, Ma E, et al. Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma. Cancer Drug Resist. 2025;8:10.
41. Kmiec D, Lista MJ, Ficarelli M, Swanson CM, Neil SJD. S-farnesylation is essential for antiviral activity of the long ZAP isoform against RNA viruses with diverse replication strategies. PLoS Pathog. 2021;17:e1009726.
